Ireland
--:--IST
Priya Life Science Compound trial record
Compound · clinical trials

Carboplatin (AUC 6) clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 4 trials in our USA, China, South Korea, Taiwan, Singapore, Spain, Poland and Australia registers that name Carboplatin (AUC 6) as an intervention. Synced 10 Nov 2026
4Current trials
2Recruiting now
3Lead sponsors
8Country registers
At a glance

Carboplatin (AUC 6) is named as an intervention in 4 current clinical trials in our USA, China, South Korea, Taiwan, Singapore, Spain, Poland and Australia registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Tang-Du Hospital (2). The most-studied condition is Head & Neck Cancer.

Patient leaflets for Carboplatin (AUC 6)

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting250%
  • Not yet open125%
  • Active, closed125%

Trials by phase

  • Phase 2250%
  • Phase 1/2125%
  • Phase 1125%
01

Clinical trials of Carboplatin (AUC 6)

4 trials
StudyPhaseStatusLead sponsorRegisters
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
NCT07353723 · ClinicalTrials.gov ↗ · Head & Neck Cancer
Phase 2 Recruiting Tang-Du Hospital China
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766 · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer
Phase 1/2 Recruiting Inhibrx Biosciences, Inc USA, South Korea, Taiwan, Singapore
Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma
NCT07752394 · ClinicalTrials.gov ↗ · Head & Neck Cancer
Phase 2 Not yet open Tang-Du Hospital China
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
NCT05117476 · Advanced Solid Tumor, NSCLC
Phase 1 Active, closed Cullinan Therapeutics Inc USA, Spain, Poland, Australia

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with Carboplatin (AUC 6)

7 conditions
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Tang-Du Hospital2
Inhibrx Biosciences, Inc1
Cullinan Therapeutics Inc1
04

By country register

RegisterTrialsRecruiting
Clinical trials in USA21
Clinical trials in China21
Clinical trials in South Korea11
Clinical trials in Taiwan11
Clinical trials in Singapore11
Clinical trials in Spain10
Clinical trials in Poland10
Clinical trials in Australia10

A trial with sites in more than one country appears in each of those registers.

05

Related compounds

06

Questions about Carboplatin (AUC 6) trials

How many clinical trials are testing Carboplatin (AUC 6)?

4 current trials in our USA, China, South Korea, Taiwan, Singapore, Spain, Poland and Australia registers name Carboplatin (AUC 6) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Carboplatin (AUC 6) trials recruiting patients?

Yes. 2 of the 4 trials are recruiting: 1 with sites in USA, 1 with sites in China, 1 with sites in South Korea, 1 with sites in Taiwan and 1 with sites in Singapore. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Carboplatin (AUC 6) clinical trials?

Tang-Du Hospital (2), Inhibrx Biosciences, Inc (1) and Cullinan Therapeutics Inc (1). The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Carboplatin (AUC 6) works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Carboplatin (AUC 6) works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Carboplatin (AUC 6) (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.